RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2022 -- Pappas Capital, a global venture capital and commercial development firm, announced today the appointment of Richard Staub as Venture Partner. His appointment...
Serono and Syntonix Sign Worldwide Agreement to Develop and Commercialize an Inhaleable Interferon-Beta Therapy for Multiple Sclerosis
News | 03. 31. 2005
Syntonix Pharmaceuticals
Serono (virt-x: SEO and NYSE: SRA) and Syntonix Pharmaceuticals Inc. announced today that they have entered into an agreement under which Serono has licensed worldwide exclusive rights to Syntonix’ TransceptorTM and SynFusionTM technologies for the development and commercialization of interferon-beta:Fc products.
